Helius Medical Technologies to Present at NobleCon19 Annual Conference
- None.
- None.
NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows:
| Date: | Tuesday, December 5, 2023 |
| Time: | 2:00pm ET |
| Location: | Boca Raton, Florida |
Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management on Monday, December 4th or Tuesday, December 5th are asked to contact NobleCon.
A webcast of the presentation will be available the following day in the Investors section of the Company’s website at ir.heliusmedical.com. The webcast will be archived on the NobleCon website and on Channelchek.com for 90 days following the event.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What is the company name and ticker symbol for the neurotech company presenting at NobleCon 19th Annual Emerging Growth Equity Conference?
What is the focus of Helius Medical Technologies, Inc.?
When and where will the presentation take place?
How can investors schedule a 1-on-1 meeting with Helius management?
Where can the webcast of the presentation be accessed?
